Catheter Precision, Inc. Announces $1.5 Million Private Placemen
Summary
The strategic move aims to expand into general cardiology and office-oriented product lines.Catheter Precision, Inc. (VTAK), a leading medical device company specializing in cardiac electrophysiology, has successfully secured $1.5 million in capital through a private placement equity financing. This structure is designed to bolster the companys financial position and facilitate strategic expansion.In addition to the equity financing, Catheter Precision has acquired promissory notes from QHSLab, Inc., valued at approximately $1.6 million. These notes are currently in default, accruing an 18% interest rate, and their valuation remains uncertain with no promise of complete repayment. Nevertheless, the acquisition is aimed at enabling Catheter Precision to broaden its market presence from hospital-based cardiac electrophysiology products to include general cardiology and office-oriented product lines.The strategic partnership with QHSLab will potentially allow Catheter Precision to leverage diagnostic solutions across mental health, cardiology, drug compliance, and allergy analyses, thereby enhancing its product offerings in physician marketplaces. Ladenburg Thalmann & Co. served as the exclusive placement agent for these transactions, further underscoring the strategic significance of this financial and operational maneuver.